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Abstract
Background: Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small
cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinum doublet.
However, treatment for patients beyond the first line remains undefined.
Case presentation: We report the case of a patient with stage IB LCNEC (PD-L1 negative but positive for PD-L1
amplification and tumor mutation burden high) who progressed after adjuvant chemotherapy after surgery and
subsequent therapy with an antibody drug conjugate targeting a neuroendocrine-specific cell surface marker but
achieved a significant and durable response with pembrolizumab, a humanized IgG4 monoclonal anti-PD-1 antibody.
Conclusions: Immunotherapy with checkpoint inhibitors is an effective treatment option for patients with metastatic
LCNEC, even if PD-L1 expression is negative.
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Background
Pulmonary large cell neuroendocrine carcinoma (LCNEC)
is a rare and aggressive tumor, diagnosed based on high-
grade features of greater than 10 mitotic figures in 2 mm2
and the presence of neuroendocrine markers [1]. Its prog-
nosis and treatment mirror that of small cell lung cancer
(SCLC), with a 5-year survival rate for stage IV disease of
less than 5% [1]. Compared with SCLC, however, LCNECs
tend to present peripherally rather than centrally and are
more likely to be early stage at diagnosis. Although there
is no prospective studies guiding treatment, extrapolation
based on studies performed in SCLC recommend surgical
resection for early, localized disease [2]. The GFPC 0302,
a phase II study, showed that the cisplatin and etoposide
combination yielded similar outcome in LCNEC as in
SCLC, with a median progression-free survival (PFS) of
5.2 months and overall survival (OS) of 7.7 months [3].
Recent genomic profiling efforts also revealed similarities
between SCLC and LCNEC, with frequent concurrent loss
of function mutations in TP53 and RB1 (~40%) [4–6]. In
addition, this group harbors higher rates of MYC amplifi-
cation (~15% in contrast to 6% in SCLC) [6]. The median
tumor mutation burden (TMB) of LCNEC and SCLC are
similar at 9.9 mutations/megabases, reflecting that both
disease entities are commonly associated with the higher
mutational load seen in smoking induced malignancies
[6]. A second group, however, does not have TP53 and
RB1 but instead possesses frequent mutations in KRAS,
STK11, NOTCH1–4, and KEAP1, which are more fre-
quently seen in non-small cell lung cancer (NSCLC) [4].
The implication for treatment and responses between
these two subsets are not yet clear. Given the dismal poor
overall survival rates in LCNECs, new treatment ap-
proaches for the disease are needed. Although there have
been a paucity of data on PD-L1 expression in LCNEC,
the recent successes of checkpoint inhibitors in relapsed
SCLC after platinum chemotherapy in the phase I/II
CheckMate 032 trial suggest that this might be a promis-
ing class of agents in LCNEC as well [7].
Case Presentation
We report a case of a 64 year-old Asian man with a 40
pack-year history of smoking who presented with
hemoptysis. Chest X-ray revealed a 3 cm right upper
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lobe nodule. CT of the chest showed a lobulated
4.2 × 4.2 × 4.8 cm lesion located in the posterior
segment of the right upper lobe abutting the T3 vertebra
and a 3.5 mm nodule in the right lower lobe which was
deemed non-specific. CT guided biopsy initially
suggested lung adenocarcinoma that was CK7 positive,
TTF-1, CK5/6, 20 and p63 negative. In addition to
moderate amount of centrilobar emphysema, PET-CT
confirmed a FDG avid lesion spanning 4.7 × 4.9 cm with
SUV of 15.8 in the right upper lobe abutting the major
fissure, a 5 mm nodule in the right lower lobe too small
to characterize, and greater than 1 cm level 10–14
lymph nodes with SUV of 3.3. Subsequent brain MRI
was negative. A right upper lobectomy and lymph node
dissection were performed. A total of 15 lymph nodes
spanning levels 2, 3, 4, 7, 10, and 11 were examined and
all were negative for cancer. Pathology showed a 4.7 cm
poorly differentiated carcinoma with possible squamous
differentiation, 1.5 cm and 1 cm from the parenchymal
and bronchial margin respectively, pT2aN0M0 stage IB.
Focal large blood vessel invasion was identified but with-
out lymphatic, perineural or pleural invasion. Immuno-
histochemical staining was negative for TTF-1, Napsin,
p40, CK5/6, and the androgen receptor but positive for
CK7, synaptophysin and CD56, consistent with a large
cell neuroendocrine carcinoma of pulmonary origin
(Fig. 1). Greater than 20 mitosis were seen in 10 high
power field. Because the tumor was high risk based on
the Encore Clinical Multi-Gene Assay for Early Stage
Lung Cancer, which predicts an 5-year overall survival of
44.6% [8, 9], the patient received 4 cycles of adjuvant
cisplatin and docetaxel chemotherapy based on the TAX
326 study [10].
Within 4 months of completing adjuvant chemother-
apy, the patient developed excruciating right hip pain.
PET-CT revealed hypermetabolism at the right acetabu-
lum and the inferolateral iliac wing (SUV 10) with cor-
tical irregularity and “moth-eaten” erosion, concerning
for metastatic infiltration. Biopsy of the right ilium
showed a high-grade tumor identical to patient’s
resected LCNEC. CK7, synaptophysin and CD56 were
positive. At this point, the original surgical specimen
was sent for molecular profiling (FoundationOne, Foun-
dation Medicine, Cambridge). Genomic alterations iden-
tified included CD274 (PD-L1) amplification, MYC
amplification, STK11 (LKB), APC, RB1, and TP53 muta-
tions (Table 1). Tumor mutation burden was high at
24.76 mutations/megabases. Initial PD-L1 staining using
the SP142 antibody was negative (Foundation Medicine,
Cambridge) and independent confirmatory testing with
a second 22C3 antibody (Cancer Genetics, Los Angeles)
also showed <1% PD-L1 expression on the tumor cells.
However, the tumor was positive for a neuroendocrine
specific cell surface marker so patient received palliative
radiation to the right hip and was enrolled in a phase I/
II study of an antibody drug conjugate targeting this spe-
cific cell surface protein.
Unfortunately, after one dose of the experimental
drug, patient’s disease progressed with increase in both
Fig. 1 Pathologic findings. a Section from the initial surgical resection
specimen shows a malignant neoplasm composed of solid nests of
epithelioid cells with large, irregular, hyperchromatic nuclei, occasional
prominent nucleoli, and abundant eosinophilic cytoplasm. There are
numerous mitotic figures, and necrosis is seen in the centers of some
of the tumor nests. b Biopsy of the iliac bone lesion shows metastatic
tumor with similar histologic features. Note abundant tumor cell
necrosis and fragments of bone within the biopsy. Insets in both
panels demonstrate positive immunohistochemical staining for
synapthophysin. [200× magnification; bar – 200 μm]
Table 1 Genomic Alterations Identified by Hybrid Capture
Gene Alteration Loss or Gain
of Function
Predictor of Response
to Pembrolizumab
CD274 (PD-L1) amplification Gain Yes
STK11 S216F and LOH Loss Negative predictor
MYC amplification Gain No
APC E2516 Loss No
RB1 Loss No
TP 53 R158 L Loss No
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the size and number of pulmonary nodules. Two new
pancreatic lesions were also identified (Fig. 2). Patient
stopped the trial and started on pembrolizumab. After 1
cycle of pembrolizumab, all visible lesions shrunk and
no new lesions were seen (Fig. 2). Patient remains on
pembrolizumab with continued improvement of the
disease 6 months after.
Conclusion and Discussion
LCNECs have been found in many organs, including the
lung, stomach, uterus, ovary, and bladder [11–14]. Gen-
omic profiling using a hybrid capture based assay revealed
multiple alterations including CD274 (PD-L1) amplifica-
tion, MYC amplification, TP53 mutation, RB1 loss, and
mutations in the APC and STK11 (LKB) genes. On retro-
spective research review, there was loss of heterozygosity
(LOH) at the STK11 locus in addition to the mutation
identified, thus conferring likely a complete loss of function
of STK11. TMB was high averaging 24.76 mutations per
megabases. Surprisingly, PD-L1 protein expression was
negative by immunohistochemistry. Genomic profiling sug-
gested that the patient’s tumor more closely resembles the
small cell type with high mutation burden, TP53 and RB1
loss, and MYC amplification. However, the presence of
STK11 mutation in this patient’s tumor is more commonly
associated in LCNECs that resemble NSCLC and differs
from a recent genomic profiling report of 300 LCNEC
where RB1 alterations was mutually exclusive to STK11
mutations (p < 0.001), reflecting the underlying heterogen-
eity and possible polyclonality of this patient’s disease [6].
PD-L1 amplification, protein levels, TMB, and STK11
mutations have all been implicated as biomarkers
predictive of response to checkpoint inhibitors. While
high PD-L1 amplification, protein levels, and TMB are
generally associated with responses to checkpoint inhibi-
tors, STK11 mutations are associated with decreased ef-
ficacy, at least in NSCLC [15–17]. Of these, PD-L1
amplification has been reported in only 2–4% of lung
cancer based on The Cancer Genome Atlas (www.cbio-
portal.org) and is usually concordant with PD-L1 protein
expression, although this is not the case for our patient
[18, 19]. Within the SCLC literature, the incidence of
PD-L1 alteration is highly controversial. Mutation was
only identified in 1.6% of SCLC in the COSMIC data-
set, 0/11 large cell carcinomas, and 0/54 carcinoid-
endocrine tumors of the lung. Others reported PD-
L1protein detection in ~70–80% of the cases (cancer.-
sanger.ac.uk) [20–23]. One reason for this apparent
discrepancy may be attributed to the often lack of
large and high quality biopsy specimen for this
disease.
Here we present an index case where the a patient
with LCNEC demonstrated a robust response to check-
point inhibitors after failing several prior lines of ther-
apy, suggesting that immunotherapy is effective in this
class of disease. Interestingly, this patient had a robust
response to checkpoint inhibitors despite the tumor har-
boring homozygous loss of function mutations in STK11
and being PD-L1 protein expression negative by immu-
nohistochemistry. This example underscores the lack of
concordance amongst current biomarkers for predicting
responses to checkpoint inhibitor therapies and the need
to identify more robust biomarkers. It also suggests that
LCNEC may have inherently different biology compared
Fig. 2 CT findings. a CT chest after 1 cycle of the antibody drug conjugate with new pulmonary nodules. b CT abdomen after 1 cycle of an
experimental antibody drug conjugate against a neuroendocrine cell surface marker with a new pancreatic lesion. c Improvement in lung
nodules after 2 cycles of pembrolizumab. d Resolution of the pancreatic lesion after 2 cycles of pembrolizumab
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to SCLC and adenocarcinomas of the lung. Future stud-
ies should incorporate composite biomarkers to increase
the predictive power.
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